Extended-release niacin effective in low doses for diabetics, say UT Southwestern researchers

July 21, 2002

DALLAS - July 22, 2002 - Niacin, a medication once discouraged for the treatment of lipid abnormalities in patients with diabetes, has the potential ability, when given in low doses, to be well-tolerated and effective, according to UT Southwestern Medical Center at Dallas researchers, who led the multicenter trial.

The researchers report in today's issue of Archives of Internal Medicine that in the 148 study participants extended-release niacin (Niaspan) led to significantly improved lipid levels and minimal changes in glycemic control.

"Previous reports have shown that niacin in high doses raises blood glucose, but this trial shows that in doses of 1,000 milligrams per day and 1,500 mg/d, niacin therapy was well-tolerated and changes in glycemic control were minimal," said Dr. Scott Grundy, the study's lead author, director of the Center for Human Nutrition at UT Southwestern and holder of the Distinguished Chair in Human Nutrition. "Low doses of an extended form of niacin also had favorable effects on blood lipids and lipoproteins."

The researchers targeted niacin therapy for a condition in patients with diabetes called dyslipidemia, which is characterized by high levels of triglycerides and other lipid-related abnormalities along with depressed levels of the healthier high-density lipoprotein (HDL) cholesterol.

"Niacin therapy has been discouraged by clinicians because high doses can worsen glycemic control in patients with diabetes," said Dr. Gloria Vega, a professor of clinical nutrition and a study co-author. "In this study we evaluated the tolerance and effectiveness of niacin at low doses. This extended-release form is designed to circumvent the bothersome side effects of regular niacin, such as flushing of the skin."

During the trial, the study participants were divided into three groups. They received either 1,500 mg/d of extended-release niacin, 1,000 mg/d of extended-release niacin, or a placebo. About half of the study participants continued taking their prescribed statin drugs for cholesterol lowering during the trial, and 81 percent continued their medications for diabetes.

In the 1,500 mg/d group, HDL increased as much as 24 percent, triglycerides decreased as much as 36 percent, and the "bad" cholesterol, low-density lipoproteins (LDL), decreased by 7 percent. In the 1,000 mg/d group HDL increased by 19 percent.

Patients with diabetic dyslipipdemia are commonly treated with triglyceride-lowering drugs known as fibrates, but niacin is more effective for raising HDL, or the good cholesterol.

"Niacin clearly increases HDL cholesterol and reduces triglycerides in individuals with type 2 diabetes," Vega said.

Many of the 14 million Americans with non-insulin-dependent (type 2) diabetes are affected by dyslipidemia, which can increase the risk for cardiovascular disease. Last year, the National Institutes of Health's National Cholesterol Education Program deemed diabetes to be a very high-risk condition of cardiovascular disease.

"Most patients with diabetes will require lipid-lowering therapy," Grundy said. "The use of statins to lower LDL cholesterol is becoming routine therapy for the majority of patients; however, this study indicates that the addition of niacin to statin therapy will provide additional benefit for improvement of blood lipids and lipoproteins in patients with diabetes."

Also participating in the multicenter trial were investigators from Kos Pharmaceuticals; the Diagnostic Clinic of Houston; the International Diabetes Center in St. Louis Park, Minn.; the East-West Medical Research Institute in Honolulu; Harvard Medical School; Northwestern University Medical School; University of North Carolina at Chapel Hill School of Medicine; the Atlanta Diabetes Association; and the North Coast Institute of Diabetes and Endocrinology in Westlake, Ohio.
The study was supported by Kos Pharmaceuticals.

To automatically receive news releases from UT Southwestern via e-mail, send a message to UTSWNEWS-REQUEST@listserv.swmed.edu. Leave the subject line blank and in the text box, type SUB UTSWNEWS.

UT Southwestern Medical Center

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.